ICON Public (NASDAQ:ICLR) Given New $262.00 Price Target at Truist Financial

ICON Public (NASDAQ:ICLR) had its price target lowered by Truist Financial from $284.00 to $262.00 in a report published on Thursday,Benzinga reports. The firm currently has a buy rating on the medical research company’s stock.

A number of other research firms also recently issued reports on ICLR. JPMorgan Chase & Co. dropped their price target on ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Baird R W downgraded shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. Royal Bank of Canada reissued an “outperform” rating and set a $263.00 price objective on shares of ICON Public in a research report on Wednesday, January 15th. Barclays reduced their target price on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Finally, Leerink Partners reissued an “outperform” rating and set a $255.00 price target (down previously from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $283.92.

ICON Public Trading Up 2.0 %

Shares of ICON Public stock opened at $186.21 on Thursday. The company has a fifty day simple moving average of $204.84 and a 200-day simple moving average of $249.28. ICON Public has a 12-month low of $181.51 and a 12-month high of $347.72. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The stock has a market cap of $15.36 billion, a price-to-earnings ratio of 20.76, a PEG ratio of 1.78 and a beta of 1.19.

Institutional Investors Weigh In On ICON Public

Hedge funds and other institutional investors have recently bought and sold shares of the business. Whittier Trust Co. lifted its stake in shares of ICON Public by 12.3% in the third quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock valued at $1,155,000 after purchasing an additional 441 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its position in shares of ICON Public by 23.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock valued at $147,000 after acquiring an additional 96 shares during the period. Arkadios Wealth Advisors boosted its stake in shares of ICON Public by 5.0% during the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock worth $371,000 after acquiring an additional 62 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in shares of ICON Public by 33.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after acquiring an additional 151 shares during the period. Finally, Icon Wealth Advisors LLC raised its holdings in ICON Public by 861.1% during the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after purchasing an additional 11,840 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.